CIRM walks a tightrope on iPS research

MarketWatch quoted a CIRM press release:

CIRM applauds the creativity and value in the research reported and shares the excitement in the promise it might hold. However, it emphatically refutes assertions by opponents of embryonic stem cell research that this new study proves embryonic stem cell research is not necessary. In fact, the Harvard study poignantly points out the value of embryonic stem cell research.

Ian Wilmut bagged embryonic stem cell research a while ago.